Siragen

Siragen is a preclinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders, with a primary emphasis on Alzheimer's disease. The company's lead candidates are designed as multi-targeted small molecules that aim to inhibit the aggregation of toxic proteins such as beta-amyloid and tau, while simultaneously promoting neuroprotection and reducing neuroinflammation. Siragen's approach seeks to address the complex pathology of dementia by targeting multiple pathways early in the disease progression to halt or reverse cognitive decline. Based in the United States, the company leverages specialized screening platforms to identify compounds with optimal blood-brain barrier permeability and safety profiles.